Loading...
The developing landscape of diagnostic and prognostic biomarkers for spinal cord injury in cerebrospinal fluid and blood
Hulme, Charlotte H. Brown, Sharon J. Fuller, Heidi R. Riddell, John S. Osman, Aheed Chowdhury, Joy Kumar, Naveen Johnson, W. E. Wright, Karina T.
Hulme, Charlotte H.
Brown, Sharon J.
Fuller, Heidi R.
Riddell, John S.
Osman, Aheed
Chowdhury, Joy
Kumar, Naveen
Johnson, W. E.
Wright, Karina T.
Advisors
Editors
Other Contributors
EPub Date
Publication Date
2016-12-20
Submitted Date
Collections
Files
Loading...
Article - AAM
Adobe PDF, 294.27 KB
Other Titles
Abstract
OBJECTIVES:
The identification of prognostic biomarkers of spinal cord injury (SCI) will help to assign SCI patients to the correct treatment and rehabilitation regimes. Further, the detection of biomarkers that predict permanent neurological outcome would aid in appropriate recruitment of patients into clinical trials. The objective of this review is to evaluate the current state-of-play in this developing field.
SETTING:
Studies from multiple countries were included.
METHODS:
We have completed a comprehensive review of studies that have investigated prognostic biomarkers in either the blood or cerebrospinal fluid (CSF) of animals and humans following SCI.
RESULTS:
Targeted and unbiased approaches have identified several prognostic biomarkers in CSF and blood. These proteins associate with cellular damage following SCI and include components from neurons, oligodendrocytes and reactive astrocytes, that is, neurofilament proteins, glial fibrillary acidic protein, Tau and S100 calcium-binding protein β. Unbiased approaches have also identified microRNAs that are specific to SCI, as well as other cell damage-associated proteins.
CONCLUSIONS:
The discovery and validation of stable, specific, sensitive and reproducible biomarkers of SCI is a rapidly expanding field of research. So far, few studies have utilised unbiased approaches aimed at the discovery of biomarkers within the CSF or blood in this field; however, some targeted approaches have been successfully used. Several studies using various animal models and some with small human patient cohorts have begun to pinpoint biomarkers in the CSF and blood with putative prognostic value. An increased sample size will be required to validate these biomarkers in the heterogeneous clinical setting.
Citation
Hulme, C. H., Brown, S. J., Fuller, H. R., Riddell, J., Osman, A., Chowdhury, J., Kumar, N., Johnson, W. E., & Wright, K. T. (2017). The developing landscape of diagnostic and prognostic biomarkers for spinal cord injury in cerebrospinal fluid and blood. Spinal Cord, 55(2), 114-125. https://doi.org/10.1038/sc.2016.174
Publisher
Springer Nature
Journal
Spinal Cord
Research Unit
DOI
10.1038/sc.2016.174
PubMed ID
PubMed Central ID
Type
Article
Language
en
Description
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1038/sc.2016.174
Series/Report no.
ISSN
EISSN
1476-5624